Nestlé re­con­sid­ers peanut al­ler­gy pro­gram two years af­ter $2.6B buy­out

It seems Nestlé is ex­pe­ri­enc­ing some buy­er’s re­morse two years af­ter throw­ing down $2.6 bil­lion for Aim­mune Ther­a­peu­tics and its peanut al­ler­gy pill Pal­forzia. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER